GlassScriptPhysician profile
George B Demetrion
NPI 1326048950
$13,098.16
in general payments reported to CMS, 2019-2025
53 companies · $1,923 in 2025
The $1,923 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,822 · 2020: $993 · 2021: $2,215 · 2022: $2,089 · 2023: $2,062 · 2024: $1,994 · 2025: $1,923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,979.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,662.32 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Amgen INC. | $1,653.28 | 2019-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $875.20 | 2019-2025 | Jardiance, Ofev, Jascayd |
| Astrazeneca Pharmaceuticals LP | $848.70 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $827.14 | 2020-2025 | Arexvy, Shingrix, Bexsero |
| Lilly USA, LLC | $776.89 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $688.08 | 2019-2024 | Xarelto, Spravato |
| Merck Sharp & Dohme LLC | $597.58 | 2019-2025 | Capvaxive, Pifeltro, Delstrigo |
| Pfizer INC. | $571.66 | 2019-2025 | |
| Viiv Healthcare Company | $394.57 | 2020-2025 | Dovato, Apretude, Cabenuva |
| Novo Nordisk INC | $388.15 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Gilead Sciences, INC. | $332.75 | 2019-2025 | Yeztugo |
| Allergan, INC. | $265.10 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $250.00 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $248.25 | 2020-2025 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Demetrion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.